Cycloset (Bromocriptine Mesylate) Patent Expiration, LOE Window & CMS Spending
Cycloset (Bromocriptine Mesylate) by Veroscience: FDA Orange Book LOE 2032-04-30, 2 AB generics, $2.8M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Veroscience |
| FDA Application & Pathway | N020866 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2032-04-30 |
| Orange Book Patents (*PED Extensions) | 13 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 2 |
| 2024 CMS Total Public Spend | $2.8M |
| 2024 Medicare Part D Spend | $2.4M |
| 2024 Medicaid Spend | $369K |
| Reported Wholesale Price Change (CA SB 17) | 2 WAC filings (max 24.9% 2-yr change) |